PER percheron therapeutics limited

atl1102 a clear winner, page-5

  1. 1,496 Posts.
    In the ann dated 20 Sept 2011 on ATL1102, ANP stated the comparison value of another Stem Cell Mobilisation therapy, Mobobil:

    "One such complimentary therapy, Mozobil, has been approved for use in combination with the main agent G-CSF. First marketed in 2009, MozobilTM sales in 2010 were ~US$100Mill with peak sales potential estimated at US$350Mill per annum."
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
0.9¢
Change
0.001(12.5%)
Mkt cap ! $9.786M
Open High Low Value Volume
0.9¢ 0.9¢ 0.9¢ $6.11K 690K

Buyers (Bids)

No. Vol. Price($)
23 6305225 0.8¢
 

Sellers (Offers)

Price($) Vol. No.
0.9¢ 1171332 5
View Market Depth
Last trade - 14.32pm 10/07/2025 (20 minute delay) ?
PER (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.